Clinical trials · Pennsylvania
Sarcoma clinical trials in Pennsylvania
We’re tracking 31 recruiting sarcoma studies with a site in Pennsylvania — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT05711615RecruitingPhase 1
Low-dose doxorubicin plus peposertib for advanced sarcoma
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05333458RecruitingPhase 2
Atezolizumab plus selinexor for advanced alveolar soft tissue sarcoma
This Phase 2 trial tests whether combining atezolizumab with selinexor can slow or shrink advanced alveolar soft part sarcoma (ASPS) in people age 12 and older. It may help by improving the immune system’s ability to fight the cancer and stopping cancer cell growth signals.
Pittsburgh, PennsylvaniaAges 12 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03016819RecruitingPhase 3
Test drugs anlotinib and catequentinib for advanced sarcoma
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05734066RecruitingPhase 1/Phase 2
Lurbinectedin drug study for young people with Ewing sarcoma
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
Philadelphia, PennsylvaniaAges 2–30 - NCT06156410RecruitingPhase 1
Cabozantinib and ifosfamide for relapsed sarcomas
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
Philadelphia, PennsylvaniaAges 5–40 - NCT06465199RecruitingPhase 1/Phase 2
Eflornithine and AMXT 1501 for Advanced Childhood Cancers
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
Hershey, PennsylvaniaAges Up to 26 years - NCT06263231RecruitingPhase 3
Study of INT230-6 injection for soft tissue sarcoma
This study tests an experimental drug, INT230-6, injected directly into tumors, compared to the usual treatments for soft tissue sarcoma. It aims to see if the injection is safe and works better for people whose cancer has not responded to earlier treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05634369RecruitingPhase 1/Phase 2
NK cell and chemotherapy trial for relapsed soft tissue sarcoma
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
Philadelphia, PennsylvaniaAges 2–40 - NCT03715933RecruitingPhase 1
Test drug INBRX-109 for advanced or metastatic solid tumors
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Philadelphia, PennsylvaniaAges 12–85 - NCT04031677RecruitingPhase 3
Surgery with or without chemotherapy for high-risk retroperitoneal sarcoma
This trial studies whether adding chemotherapy before surgery helps people with high-risk retroperitoneal (abdominal-area) leiomyosarcoma or liposarcoma. The goal is to improve outcomes while comparing surgery alone versus surgery plus neoadjuvant chemotherapy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04305691RecruitingPhase 2
Ixazomib for skin Kaposi sarcoma in people with HIV
This trial studies ixazomib (a targeted anti-cancer medicine) to treat cutaneous (skin) Kaposi sarcoma. It aims to shrink measurable skin lesions and improve symptoms, especially in people living with HIV.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Pittsburgh, PennsylvaniaAges 1–30 - NCT05910307Recruiting
Registry study for people with synovial sarcoma
This study builds a database and collects tissue/blood samples from people diagnosed with synovial sarcoma. Sharing samples may help researchers better understand the disease and improve future care.
Philadelphia, PennsylvaniaAges Any age - NCT05918640RecruitingPhase 1/Phase 2
Lurbinectedin for cancers with specific EWS-related gene fusions
This early-phase study tests lurbinectedin, a chemotherapy medicine, in children and young adults whose solid tumors have a specific “FET fusion” gene change. It may help shrink tumors that have come back or did not respond to prior treatment, depending on the exact fusion type.
Philadelphia, PennsylvaniaAges 10 years+ - NCT06436846Recruiting
Genomic risk in retroperitoneal sarcoma
This study is looking at genetic risk factors in people with retroperitoneal liposarcoma who are having surgery to remove the tumor. The goal is to understand how genes affect the disease and possibly guide future treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07321912RecruitingPhase 2
Eflornithine (DFMO) for Ewing sarcoma and osteosarcoma
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
Hershey, PennsylvaniaAges birth–50 years - NCT07436364RecruitingEarly Phase 1
Ultrasound to monitor sarcoma response to radiation
This trial uses contrast-enhanced ultrasound to see how well soft tissue sarcoma responds to radiation therapy given before surgery. The goal is to find out if this imaging method can help doctors assess treatment effects earlier.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03959800Recruiting
Study of the causes of childhood liver tumors
This study looks at why childhood liver tumors happen by using samples and information from children who have had a liver tumor and from their close family members. It may help researchers understand the biology of these tumors and guide better treatments in the future.
Pittsburgh, PennsylvaniaAges birth–99 years - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Allentown, PennsylvaniaAges 40–75 - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Philadelphia, PennsylvaniaAges 6 months–25 years - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Philadelphia, PennsylvaniaAges 18–130 - NCT04370587RecruitingPhase 1/Phase 2
Injecting a cancer medicine into tumors plus pembrolizumab
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04719156RecruitingPhase 2
Fluorescent dye to check tumor margins during surgery
This Phase 2 study tests whether using a fluorescent dye during tumor surgery can help the surgical team better see where the tumor ends. It may help aim for complete removal and lower the chance of the tumor coming back.
Pittsburgh, PennsylvaniaAges 18–100
Sarcoma trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting sarcoma studies listed above.
- Children's Hospital of Philadelphia · 8 studies
- University of Pennsylvania · 5 studies
- Fox Chase Cancer Center · 4 studies
- Thomas Jefferson University Hospital · 4 studies
- UPMC Hillman Cancer Center · 4 studies
- Allegheny General Hospital · 2 studies
- Penn State Health Children's Hospital · 2 studies
- Pennsylvania Hospital · 2 studies
What taking part in a sarcoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Sarcoma trials in other states
Common questions
- Are there sarcoma clinical trials in Pennsylvania?
- Yes. We're currently tracking 31 recruiting sarcoma studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a sarcoma study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a sarcoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New sarcoma studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.